Subject
Gastroenterology,Hepatology
Reference10 articles.
1. Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab;Sousa;Dig Liver Dis,2023
2. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease;Cosnes;Aliment Pharmacol Ther,2016
3. Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study;Targownik;Clinic Gastroenterol Hepatol,2019
4. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents;Kestens;Clinic Gastroenterol Hepatol,2013
5. Comparative effectiveness of infliximab and adalimumab for Crohn's disease;Clinic Gastroenterol Hepatol,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献